bluuebunny/crossref_metadata_2025_split huggingface dataset:
Methods and research progress in the construction of animal models of osteosarcopenia: a scoping review
Authors: Weiwei  , Wang Shixuan , Hou Decai , Zhan Libin 
Published: October 2023

BackgroundOsteosarcopenia(OS) is a significant health concern resulting from the ageing process. Currently, as the population grows older, the prevalence of OS, a disease that entails the synchronous degeneration of muscles and bones, is mounting. This poses a serious threat to the health of the elderly while placing an enormous burden on social care. In order to comprehend the pathological mechanism of OS and develop clinical drugs, it is pertinent to construct an efficient animal model of OS. To investigate the modeling techniques of diverse experimental models of OS and elucidate their respective benefits and drawbacks, with the purpose of furnishing a theoretical foundation to advance experimental research on OS.MethodsWe searched PubMed, Embase database, China Knowledge Network, Wanfang data platform and Vipshop journal platform databases from 2000 through to September 1, 2023. We included animal studies on sarcopenia or osteoporosis or osteosarcopenia or sarcopenia-osteoporosis, modeling methods for osteosarcopenia. Two independently screened study abstracts and full reports and complete data extraction.ResultsEventually, Of 112, 106 citations screened. 4938 underwent full-text review and 38 met the inclusion criteria. we reviewed and analyzed the literature and categorized the animal models of OS into the following five categories: Aging OS models; Hormonal deficiency model of OS;Chemical injection to induce OS;Disuse OS models and Genetic engineering OS models.ConclusionThis review outlines animal modeling approaches for OS, providing a comprehensive summary of their advantages and disadvantages. The different models were evaluated and selected based on their respective strengths and weaknesses to enable higher quality research outcomes in various research directions. The most widely used and established approach is considered to be the ageing and chemical injection OS model, which has the advantages of excellent reproducibility and low cost.The translational potential of this articleTo gain a profound comprehension of the pathological mechanism of OS and to devise efficacious clinical treatments, it is imperative to establish a viable laboratory animal model of OS. This article surveys various modeling techniques assessing their benefits, drawbacks and areas of applicability while predominantly employing mice as the primary model animal. Additionally, the evaluation indicators of OS models are briefly described.
Exploring the role of gut microbiota in autoimmune thyroid disorders: a systematic review and meta-analysis
Authors: Alkader Dania Akeil Abed , Asadi Naweedullah , Solangi Uzma , Singh Ransherjit , Rasuli Sayed Farhad , Farooq Muhammad Jawad , Raheela F. N. U. , Waseem Radeyah , Gilani Syed Mujahid , Abbas Kiran , Ahmed Moiz , Tanoh Desmond Boakye , Shah Hussain Haider , Dulal Ayusha , Hussain Muhammad Sheheryar , Talpur Abdul Subhan 
Published: October 2023

BackgroundAutoimmune thyroid diseases (AITDs) are characterized by unique immune responses against thyroid antigens and persist over time. The most common types of AITDs are Graves&amp;apos; disease (GD) and Hashimoto&amp;apos;s thyroiditis (HT). There is mounting evidence that changes in the microbiota may play a role in the onset and development of AITDs.ObjectiveThe purpose of this comprehensive literature study was to answer the following query: Is there a difference in microbiota in those who have AITDs?MethodsAccording to the standards set out by the PRISMA statement, 16 studies met the requirements for inclusion after being screened for eligibility.ResultsThe Simpson index was the only diversity measure shown to be considerably lower in patients with GD compared to healthy participants, whereas all other indices were found to be significantly greater in patients with HT. The latter group, however, showed a greater relative abundance of Bacteroidetes and Actinobacteria at the phylum level, and consequently of Prevotella and Bifidobacterium at the genus level. The strongest positive and negative relationships were seen for thyroid peroxidase antibodies and bacterial load.ConclusionOverall, both GD and HT patients showed significant changes in the gut microbiota&amp;apos;s diversity and composition.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023432455.
A short-term high-fat diet alters rat testicular activity and blood-testis barrier integrity through the SIRT1/NRF2/MAPKs signaling pathways
Authors: Falvo Sara , Minucci Sergio , Santillo Alessandra , Senese Rosalba , Chieffi Baccari Gabriella , Venditti Massimo 
Published: October 2023

BackgroundOverweight/obesity are metabolic disorder resulting from behavioral, environmental, and heritable causes. WHO estimates that 50% of adults and 30% of children and adolescents are overweight or obese, and, in parallel, an ongoing decline in sperm quality and male fertility has been described. Numerous studies demonstrated the intimate association between overweight/obesity and reproductive dysfunction due to a highly intricate network of causes not yet completely understood. This study expands the knowledge on the impact of a short-term high-fat diet (st-HFD) on rat testicular activity, specifically on steroidogenesis and spermatogenesis, focusing on the involved molecular mechanisms related to mitochondrial dynamics, blood-testis barrier (BTB) integrity, and SIRT1/NRF2/MAPKs pathways.MethodsTen adult Male Wistar rats were divided into two groups of five and treated with a standard diet or an HFD for five weeks. At the end of the treatment, rats were anesthetized and sacrificed by decapitation. Blood was collected for serum sex hormone assay; one testis was stored at -80ÅãC for western blot analysis, and the other, was fixed for histological and immunofluorescence analysis.ResultsFive weeks of HFD results in reduced steroidogenesis, increased apoptosis of spermatogenic cells, and altered spermatogenesis, as highlighted by reduced protein levels ofmeiotic and post-meiotic markers. Further, we evidenced the compromission of the BTB integrity, as revealed by the downregulation of structural proteins (N-Cadherin, ZO-1, occludin, connexin 43, and VANGL2) other than the phosphorylation of regulative kinases (Src and FAK). At the molecular level, the impairment of mitochondrial dynamics (fission, fusion, andbiogenesis), and the dysregulation of the SIRT1/NRF2/MAPKs signaling pathways, were evidenced. Interestingly, no change was observed in the levels of pro-inflammatory markers (TNFα, NF-kB, and IL-6).ConclusionsThe combined data led us to confirm that overweight is a less severe state than obesity. Furthermore, understanding the molecular mechanisms behind the association between metabolic disorders and male fertility could improve the possibility of identifying novel targets to prevent and treat fertility disorders related to overweight/obesity.
Predictors of willingness to accept COVID-19 vaccine among adults
Authors: Huka Alo Edin , Alemeyehu Lami , Jara Dube , Ayele Angefa , Shifa Tofik 
Published: October 2023

BackgroundVaccines are an effective and ultimate solution that can decrease the burden of coronavirus disease 2019 worldwide. However, poor knowledge and unwillingness to accept this vaccine are key barriers to manage the COVID-19 pandemic in different countries including Ethiopia. Control of the pandemic will depend on the acceptance of coronavirus disease vaccine. However, there is a paucity of evidence on coronavirus disease vaccine acceptance in the study area. The current study was aimed to assess willingness to accept the COVID-19 vaccine and associated factors among adult clients attending Bule Hora University Teaching Hospital, West Guji Zone, southern Ethiopia.MethodsAn institution-based cross-sectional study was conducted among 385 study participants selected by a systematic random sampling technique. Data was collected through observation and structured questionnaires from April 10 to May 30, 2022. The collected data was cleaned and entered into EpiData 3.1 software before being exported to SPSS 25 statistical software for analysis. Bi-variable and multi-variable binary logistic regression model was used to identify the predictors of COVID-19 vaccine acceptance. The strength of association was measured using AOR with 95% confidence interval and significance was declared at p- value &lt; 0.05.ResultMagnitude of willingness to accept coronavirus disease-19 vaccine was 67.5% (95%Cl: 63–72). Good knowledge [AOR = 2.07, (1.17–3.64)], history of chronic disease [AOR = 2.59, (1.4–4.78)], being a government employee [AOR = 2.35 (1.1–5)], having a favorable attitude [AOR = 14.15 (5.25–37.46)], and good adherence [AOR = 1.74 (1.02–2.97)] were factors that significantly associated with willingness to accept the coronavirus disease 2019 vaccine.ConclusionMagnitude of willingness to accept the COVID-19 vaccine was considerable and needs to be improved. Knowledge, attitude, chronic illness, adherence, and being a government employee were factors that associated with willingness to accept the vaccine. Community awareness, advocacy, social mobilization and health education should be given at different levels.
Mediport use as an acceptable standard for CAR T cell infusion
Authors: Eylon Maya , Prabhu Snehit , John Samuel , King Maxwell J. M. , Bhatt Dhruv , Curran Kevin J. , Erickson Courtney , Karras Nicole A. , Phillips Christine L. , Satwani Prakash , Hermiston Michelle , Southworth Erica , Baumeister Susanne H. C. , Talano Julie-An , MacMillan Margaret L. , Rossoff Jenna , Bonifant Challice L. , Myers Gary Doug , Rouce Rayne H. , Toner Keri , Driscoll Timothy A. , Katsanis Emmanuel , Salzberg Dana B. , Schiff Deborah , De Oliveira Satiro N. , Capitini Christian M. , Pacenta Holly L. , Pfeiffer Thomas , Shah Niketa C. , Huynh Van , Skiles Jodi L. , Fraint Ellen , McNerney Kevin O. , Quigg Troy C. , Krueger Joerg , Ligon John A. , Fabrizio Vanessa A. , Baggott Christina , Laetsch Theodore W. , Schultz Liora M. 
Published: October 2023

IntroductionMediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and ineffective therapy delivery to systemic circulation has resulted in variable practice with intravenous administration of CAR T cell therapy. With CAR T cell commercialization, it is important to establish practice standards for CAR T cell delivery. We conducted a study to establish usage patterns of mediports in the clinical setting and provide a standard of care recommendation for mediport use as an acceptable form of access for CAR T cell infusions. MethodsIn this retrospective cohort study, data on mediport use and infiltration rate was collected from a survey across 34 medical centers in the Pediatric Real-World CAR Consortium, capturing 504 CAR T cell infusion routes across 489 patients. Data represents the largest, and to our knowledge sole, report on clinical CAR T cell infusion practice patterns since FDA approval and CAR T cell commercialization in 2017. ResultsAcross 34 sites, all reported tunneled central venous catheters, including Broviac® and Hickman® catheters, as accepted standard venous options for CAR T cell infusion. Use of mediports as a standard clinical practice was reported in 29 of 34 sites (85%). Of 489 evaluable patients with reported route of CAR T cell infusion, 184 patients were infused using mediports, with no reported incidences of CAR T cell infiltration. Discussion/ConclusionBased on current clinical practice, mediports are a commonly utilized form of access for CAR T cell therapy administration. These findings support the safe practice of mediport usage as an accepted standard line option for CAR T cell infusion.
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
Authors: Urwyler Pascal , Leimbacher Marina , Charitos Panteleimon , Moser Stephan , Heijnen Ingmar A. F. M. , Trendelenburg Marten , Thoma Reto , Sumer Johannes , Camacho-Ortiz Adrián , Bacci Marcelo R. , Huber Lars C. , Stüssi-Helbling Melina , Albrich Werner C. , Sendi Parham , Osthoff Michael 
Published: October 2023

BackgroundConestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation.MethodsWe conducted a randomized, open-label, multi-national clinical trial in which hospitalized adults at risk for progression to severe COVID-19 were assigned in a 2:1 ratio to receive either 3 days of ConA plus standard of care (SOC) or SOC alone. Primary and secondary endpoints were day 7 disease severity on the WHO Ordinal Scale, time to clinical improvement within 14 days, and safety, respectively.ResultsThe trial was prematurely terminated because of futility after randomization of 84 patients, 56 in the ConA and 28 in the control arm. At baseline, higher WHO Ordinal Scale scores were more frequently observed in the ConA than in the control arm. On day 7, no relevant differences in the primary outcome were noted between the two arms (p = 0.11). The median time to defervescence was 3 days, and the median time to clinical improvement was 7 days in both arms (p = 0.22 and 0.56, respectively). Activation of plasma cascades and endothelial cells over time was similar in both groups. The incidence of adverse events (AEs) was higher in the intervention arm (any AE, 30% with ConA vs. 19% with SOC alone; serious AE, 27% vs. 15%; death, 11% vs. 0%). None of these were judged as being related to the study drug.ConclusionThe study results do not support the use of ConA to prevent COVID-19 progression.Clinical trial registrationhttps://clinicaltrials.gov, identifier NCT04414631.
Pleiotropic effects of Mentha longifolia L. extract on the regulation of genes involved in inflammation and apoptosis induced by Clostridioides difficile ribotype 001
Authors: Raeisi Hamideh , Azimirad Masoumeh , Abdemohamadi Elham , Pezzani Raffaele , Zali Mohammad Reza , Yadegar Abbas 
Published: October 2023

IntroductionThe dramatic increase in multidrug-resistance of Clostridioides difficile isolates has led to the search for new complementary medicines against C. difficile infection (CDI). In this study, we aimed to examine the inhibitory effects of hydroethanolic extract of Mentha longifolia L. (ETOH-ML) on the growth of C. difficile RT001 and its toxigenic cell-free supernatant (Tox-S)-induced inflammation and apoptosis.MethodsThe active phytochemical components of ETOH-ML were detected using GC and HPLC. The antimicrobial properties of the extract were examined against C. difficile RT001. Furthermore, cell viability and cytotoxicity of Caco-2 and Vero cells treated with various concentrations of ETOH-ML, Tox-S of C. difficile RT001, and their combination were assessed. Anti-inflammatory and anti-apoptotic activities of ETOH-ML were explored in Tox-S stimulated Caco-2 cells using RT-qPCR.ResultsBased on our results, rosmarinic acid was the main phytochemical component of ETOH-ML. The extract showed significant antimicrobial activity against C. difficile RT001 by agar dilution and broth microdilution methods. Moreover, ETOH-ML at concentrations of &lt;25 μg/ml had no significant effect on cell viability compared to untreated cells. Treatment cells with the extract (10 or 25 μg/ml) significantly increased the cell viability and reduced the percentage of cell rounding in Caco-2 and Vero cells treated by Tox-S, respectively (P &lt; 0.0001). Co-treatment of Tox-S stimulated Caco-2 cells with ETOH-ML showed significant anti-inflammatory and anti-apoptotic activities by downregulating the gene expression level of IL-8, IL-1β, TNF-α, iNOS, TGF-β, NF-κB, Bax, and caspase-3, while upregulating the expression level of Bcl-2.DiscussionOur results demonstrated for the first time the antimicrobial, anti-inflammatory, and anti-apoptotic effects of M. longifolia extract on C. difficile RT001 and its Tox-S. However, further research is needed to evaluate the potential application of M. longifolia extract on CDI treatment in clinical setting.
Optimizing acute stroke treatment process: insights from sub-tasks durations in a prospective observational time and motion study
Authors: Koca Gizem , Kumar Mukesh , Gubitz Gord , Kamal Noreen 
Published: October 2023

BackgroundRapid treatment is critical in managing acute ischemic stroke (AIS) to improve patient outcomes. Various strategies have been used to optimize this treatment process, including the Acute Stroke Protocol (ASP) activation, and minimizing the duration of key performance metrices, such as door-to-needle time (DNT), CT-to-needle time (CTNT), CT-to-groin puncture time (CTGP), and door-to-groin puncture time (DGPT). However, identifying the delay-causing sub-tasks within the ASP could yield novel insights, facilitating optimization strategies for the AIS treatment process.MethodsThis two-phase prospective observational time and motion study aimed to identify sub-tasks and compare their respective durations involved in the treatment process for AIS patients within ASPs. The study compared sub-task durations between “routine working hours” and “evenings and weekends” (after-hours), as well as between stroke neurologists and non-stroke neurologists. Additionally, the established performance metrices of AIS were compared among the aforementioned groups.ResultsPhase 1 identified and categorized 34 sub-tasks into five broad categories, while Phase 2 analyzed the ASP for 389 patients. Among the 185 patients included in the study, 57 received revascularization treatment, with 30 receiving intravenous (IV) thrombolysis only, 20 receiving endovascular thrombectomy (EVT) only, and 7 receiving both IV thrombolysis and EVT. Significant delays were observed in sub-tasks including triage, registration, patient history sharing, treatment decisions, preparation of patients, preparation of thrombolytic agents, and angiosuite preparation. The majority of these significant delays (P &lt; 0.05) were observed when were performed by a non-stroke neurologist and during after-hours operations. Furthermore, certain sub-tasks were exclusively performed during after-hours or when the treatment was provided by a non-stroke neurologist. Consequently, DNT, CTNT, and CTGP were significantly prolonged for both non-stroke neurologists and off-hours treatment. DGPT was significantly longer only when the ASP was conducted by non-stroke neurologists.ConclusionsThe study identified several sub-tasks that lead to significant delays during the execution of the ASP. These findings provide a premise to design targeted quality improvement interventions to optimize the ASP for these specific delay-causing sub-tasks, particularly for non-stroke neurologists and after-hours. This approach has the potential to significantly enhance the efficiency of the AIS treatment process.
Cognitive and balance functions of astronauts after spaceflight are comparable to those of individuals with bilateral vestibulopathy
Authors: Clément Gilles , Kuldavletova Olga , Macaulay Timothy R. , Wood Scott J. , Navarro Morales Deborah C. , Toupet Michel , Hautefort Charlotte , Van Nechel Christian , Quarck Gaëlle , Denise Pierre 
Published: October 2023

IntroductionThis study compares the balance control and cognitive responses of subjects with bilateral vestibulopathy (BVP) to those of astronauts immediately after they return from long-duration spaceflight on board the International Space Station.MethodsTwenty-eight astronauts and thirty subjects with BVP performed five tests using the same procedures: sit-to-stand, walk-and-turn, tandem walk, duration judgment, and reaction time.ResultsCompared to the astronauts' preflight responses, the BVP subjects' responses were impaired in all five tests. However, the BVP subjects' performance during the walk-and-turn and the tandem walk tests were comparable to the astronauts' performance on the day they returned from space. Moreover, the BVP subjects' time perception and reaction time were comparable to those of the astronauts during spaceflight. The BVP subjects performed the sit-to-stand test at a level that fell between the astronauts' performance on the day of landing and 1 day later.DiscussionThese results indicate that the alterations in dynamic balance control, time perception, and reaction time that astronauts experience after spaceflight are likely driven by central vestibular adaptations. Vestibular and somatosensory training in orbit and vestibular rehabilitation after spaceflight could be effective countermeasures for mitigating these post-flight performance decrements.
Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
Authors: Blumenfeld Andrew , Tepper Stewart J. , Khanna Rashna , Doty Erin , Vincent Maurice , Miller Sheila I. 
Published: October 2023

BackgroundSerotonin syndrome (SS) symptoms overlap with adverse events associated with lasmiditan, a 5-HT (serotonin)1F receptor agonist for acute treatment of migraine. Because SS symptoms are heterogeneous, diagnosis can be challenging, and potential cases observed with lasmiditan treatment led to questions about SS pathophysiology. Here, we provide an overview of the potential risk of SS based on experience with lasmiditan.MethodsResults of eight phase 2 and phase 3 lasmiditan trials (n = 5,916) and a controlled intravenous trial of lasmiditan (n = 88) were analyzed for symptomatology consistent with SS. Post-marketing surveillance data from lasmiditan’s US launch date (January 2020) until data cut-off (April 2021) were also examined. Established Sternbach and Hunter diagnostic criteria were used for formal determination of SS.ResultsOf 6,004 lasmiditan-treated clinical trial patients, 15 reported ≥1 treatment-emergent adverse event consistent with signs and symptom(s) of SS. After review, one case met Sternbach and Hunter criteria, two cases potentially met Sternbach criteria, and three cases reported as SS had limited/no information to determine if either criterion was met. During post-marketing surveillance (approximately 13,400 lasmiditan prescriptions), 17 cases with symptom complexes consistent with SS were reported; 3/17 cases had adequate case descriptions to apply predefined criteria. Of these, two met Sternbach and Hunter criteria, and one met Sternbach criteria.ConclusionAwareness of clinical symptomatology and diagnostic criteria of SS can help clinicians with recognition of rare instances of SS that may occur with lasmiditan.Clinical trial registrationNCT03670810, NCT00384774, NCT00883051, NCT02565186.